Sequelae of multidrug-resistant tuberculosis: protocol for a systematic review and meta-analysis

BMJ Open. 2018 Feb 10;8(2):e019593. doi: 10.1136/bmjopen-2017-019593.


Introduction: The sequelae of multidrug-resistant tuberculosis (MDR-TB) are poorly understood and inconsistently reported. We will aim to assess the existing evidence for the clinical, psychological, social and economic sequelae of MDR-TB and to assess the health-related quality of life in patients with MDR-TB.

Methods and analysis: We will perform a systematic review and meta-analysis of published studies reporting sequelae of MDR-TB. We will search PubMed, SCOPUS, ProQuest, Web of Science and PsychINFO databases up to 5 September 2017. MDR-TB sequelae will include any clinical, psychological, social and economic effects as well as health-related quality of life that occur after MDR-TB treatment or illness. Two researchers will screen the titles and abstracts of all citations identified in our search, extract data, and assess the scientific quality using standardised formats. Providing there is appropriate comparability in the studies, we will use a random-effects meta-analysis model to produce pooled estimates of MDR-TB sequelae from the included studies. We will stratify the analyses based on treatment regimen, comorbidities (such as HIV status and diabetes mellitus), previous TB treatment history and study setting.

Ethics and dissemination: As this study will be based on published data, ethical approval is not required. The final report will be disseminated through publication in a peer-reviewed scientific journal and will also be presented at relevant conferences.

Prospero registration number: CRD42017073182.

Keywords: MDR-TB; meta-analysis; multidrug-resistant tuberculosis; protocol; sequelae; systematic review.

Publication types

  • Meta-Analysis

MeSH terms

  • Antitubercular Agents / therapeutic use*
  • Comorbidity
  • Humans
  • Quality of Life*
  • Research Design
  • Systematic Reviews as Topic
  • Tuberculosis, Multidrug-Resistant / drug therapy*


  • Antitubercular Agents